Cargando…
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
PET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T) infusion at two time points: pre-leukapheresis (pre-leuk) and pre-lymphodepletion chemotherapy (pre-LD). We hypothesized that changes in PET/CT between these time points predic...
Autores principales: | Breen, William G., Young, Jason R., Hathcock, Matthew A., Kowalchuk, Roman O., Thorpe, Matthew P., Bansal, Radhika, Khurana, Arushi, Bennani, N. Nora, Paludo, Jonas, Bisneto, Jose Villasboas, Wang, Yucai, Ansell, Stephen M., Peterson, Jennifer L., Johnston, Patrick B., Lester, Scott C., Lin, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435575/ https://www.ncbi.nlm.nih.gov/pubmed/37591834 http://dx.doi.org/10.1038/s41408-023-00895-7 |
Ejemplares similares
-
The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021) -
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022) -
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
por: Acosta-Medina, Aldo A., et al.
Publicado: (2023) -
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
por: Powell, Marissa Z., et al.
Publicado: (2023) -
Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021)